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Background: Cortactin is an important regulator involved in invasion and migration of hepatocellular carcinoma
(HCC). The aim of this study was to elucidate the forecasting role of cortactin in resectable HCCs.
Methods: We compared the invasiveness and motility among liver epithelial cell line and HCC cell lines by using
Transwell assay and wound healing assay. We further investigated the CTTN mRNA expression by real-time PCR.
Next, 91 HCC and 20 normal liver tissue samples were detected by IHC and real-time PCR. Finally, we analyzed the
clinicopathologic features and survival time of the HCC cases.
Results: We identified that HepG2, LM3, and SK-Hep-1 had more invasiveness and motility (P <0.05). Compared
with liver epithelial cell line, CTTN expression was higher in LM3, HepG2, and MHCC97-L (P <0.01) and lower in
SK-Hep-1 (P <0.05). IHC examination showed cortactin expression was closely relative to TNM stage (AJCC/UICC),
cancer embolus, and metastasis (P <0.01). Cortactin overexpression indicated a longer survival time of 52 ± 8.62
months and low expression of a shorter survival time of 20 ± 4.95 months (P <0.01). Cortactin examination has
more predictive power in patients with Child-Pugh grade A and BCLC stage 0-B.
Conclusions: Overexpression of cortactin is closely associated with poor human HCCs prognosis that caused by
cancer embolus and metastasis. Cortactin and CTTN should be used for differentiating varieties of survival for
patients after HCC resection.
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Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors in the world [1]. In China,
HCC has been one of the leading causes of cancer death
despite remarkable improvement in diagnostic and
therapeutic techniques [2]. Although the prognosis
remains poor, there is no specific method to predict
long-term survival time of HCC patients [3]. Thus, dif-
ferentially subsequent treatment for HCC patients can-
not be performed after initial operation. The point of
view has been taken that poor prognosis of HCC is
mainly because of the high incidence of hematogenous
intrahepatic metastasis after initial treatment [4]. In* Correspondence: kjzygdwk@163.com
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reproduction in any medium, provided the oressence, invasiveness of hepatocarcinoma cells play a
crucial role in HCC metastasize and recurrence. Further-
more, cytoskeleton remodeling is required for tumor cell
invasion and migration [5]. The molecular closely in-
volved in cytoskeleton remodeling may be valid candi-
dates which can predict prognosis of patients with
cancer. Oligonucleotide array technology, a high-
throughput method of monitoring gene expression,
showed that the molecular signatures were apparently
different between highly metastatic HCC cell lines and
non-metastatic HCC cell lines. Among these candidates,
CTTN, a gene related to tumor cell invasion and migra-
tion, for which the encoding protein is named cortactin,
may be a potential molecular marker that can predict
prognosis of cancer patients [6]. In addition, it has been
well documented that CTTN is amplified in several
other human cancers leading to cortactin overexpressiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Cortactin immunohistochemical detection in 91
HCCs
Cortactin IHC score P
0-3 4-6












Maximal size (mm)a 6.64 ± 0.84 7.76 ± 0.66 0.531
Liver capsule integrity 0.054
Complete 34 29
Incomplete 9 19
Tumor nodules (n) 0.084
Single 34 30
Multiple 9 18
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not cause morphological changes or affect proliferation,
it makes cells more motile and invasive [9]. It has been
proved that if cortactin can be overexpressed in a non-
metastatic HCC cell line it will increase cell motility and
resulted in increased metastatic formation [6]. Con-
versely, cortactin knockdown can decrease tumor cell
motility and invasion [6,10]. Forecasting role of cortactin
has been investigated in head and neck squamous cell
carcinomas and even in HCC [6,11]. As we know, how-
ever, no study has carried out follow-up on a series of
cases with HCC. In this study, to investigate whether
cortactin and CTTN could become a sensitive and spe-
cific biomarker to predicate HCC prognosis, we first se-
lected five cell lines, including one liver epithelial cell
line and four HCC cell lines, to detect their ability of in-
vasion and migration. We then compared their expres-
sion level of CTTN mRNA. We also collected patients
who were performed hepatectomy and examined their
tissue samples. Cortactin and CTTN mRNA were exam-
ined respectively. To confirm whether cortactin and
CTTN expression are related to the survival of HCC pa-
tients, we followed up this series of cases and compared
the survival data of different expression levels.
Methods
Cell culture and liver tissue
The liver epithelial cell line, QSG-7701, and HCC cell
lines, HepG2, MHCC97-L, and SK-Hep-1, were obtained
from the Beijing Institute of Transfusion Medicine. An-
other HCC cell line, LM3, was obtained from the Chin-
ese PLA General Hospital. All the cells were maintained
in DMEM (H) supplemented with 10% fetal bovine
serum (FBS). Ninety-one random sampled HCC patients
(22 women, 69 men; mean age, 54 years) were studied
retrospectively. The patients had been recruited in the
PLA Air Force General Hospital from 2002 to 2009. All
the patients have been performed hepatectomy for re-
sectable hepatocellular carcinoma. No radiotherapy and
chemotherapy were undergone before the operation.
The other 20 hepatic haemangioma cases were randomly
sampled as the control group. The final pathological
diagnoses of 111 cases were definite. Ninety-seven tissue
blocks were acquired and refrigerated in liquid nitrogen
right after removal out of the body, including 77 HCC
tissues and 20 normal liver tissues adjacent to haemangi-
oma. In 91 HCCs, 14 tissues were not acquired to be re-
frigerated for the reason of too small tumor size or
inconvenient during operation. Patients and disease
characteristics are shown in Table 1. Sections from 91
HCC histological paraffin-embedded specimens were
used for cortactin immunohistochemistry. Seventy-seven
HCC tissue blocks and 20 normal liver tissue blocks
were analyzed by real-time PCR to investigate CTTNmRNA expression level. Written informed consent was
obtained from all patients, and this study was approved
by the Ethics Committee of Chinese PLA Air Force
General Hospital.
The determination of clinical stage
Tumor size and number, liver function test, prothrombin
time, performance status, and cancer-related symptoms
were investigated. If esophagogastric varices, ascites,
splenomegaly and a platelet count <100,000 /mm3, the
portal hypertension was defined. All patients underwent
serum α-fetoprotein (AFP), abdominal ultrasound, and
four-phase dynamic computed tomography (CT) exam-
ination. In cases with another intrahepatic nodule not
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were made by dynamic magnetic resonance imaging
(MRI) or positron emission tomography (PET)-CT. The
biopsy was applied when imageology examination
could not make a final diagnosis. The chest CT was
carried out when the patient had positive present of
diagnostic chest X-ray radiology which is as a routine
examination for all patients. A bone scan was necessary
when the patient have chief complaint of osteodynia.
The hepatic functional reserve was evaluated by Child-
Pugh grade system which was classified as A, B, and C.
BCLC stage system was applied to determine the clin-
ical stages. HCC patients were classified into five stages
including: 0, very early; A, early; B, intermediate; C, ad-
vanced; or D, terminal. Final HCC stages were deter-
mined after operation, histopathology, and a follow-up
examination [12].
Transwell invasion assay
To hydrate the matrigel layer, the upper chamber of a
transwell cell culture insert (Corning 3422) was filled
with 100 μL DMEM(H) medium without FBS and incu-
bated at 37°C for 1 h. Cells were suspended with serum-
free DMEM(H) medium to the concentration of 5 × 105
cells/mL. Filled 200 μL cell suspension to upper cham-
ber and 600 μL DMEM(H) medium with 10% FBS to the
bottom chamber. The inserts were placed in the cell
culture incubator at 37°C for 24 h. The cell was fixed
by placing each insert into 90% ethanol and the cell
was stained with 1% crystal violet for 30 min. Five high
power fields (×100) were randomly selected in each
chamber to observe the cells and Cell Counter software
was used to count the stained invaded cells. Each experi-
mental group was repeated three times.
Wound healing assay
Cells were seeded into 24-well tissue culture plate in a
density that reached 70% to 80% confluence as a mono-
layer after 24 h of growth. The monolayer was scratched
with a pipette tip across the center to create a cross in
each well. The well was washed twice with medium to
remove the detached cells. The cells were grown for
additional 96 h in fresh medium. Four views of each well
were documented and the gap distance was quantita-
tively evaluated using WCIF ImageJ software. Each ex-
perimental group was repeated three times.
Immunohistochemical staining
Labeled streptavidin-biotin peroxidase complex method
was used [13]. Immunohistochemistry with cortactin
(Cortactin Ab, 1:50; Cell Signaling) was performed on
sections of formalin-fixed (7.5% buffered formalin) and
paraffin-embedded representative tumor tissues from all
91 carcinomas. Tissue blocks were cut to 4 μm, thenmounted on silicone-coated slides, deparaffinized with
xylene, 100% ethanol and 95% ethanol by turns, and
heated in 10 mM sodium citrate buffer (pH 6.0) using a
microwave oven for 10 min at 95°C. Before primary anti-
body incubation, incubated sections in 3% hydrogen per-
oxide and blocked sections with 5% goat serum. Primary
antibodies were incubated overnight at 4°C. Biotinylated
secondary antibody and ABC avidin/biotin method was
used for visualizing positive reactions. After ABC reagent
was incubated, the sections were developed with 3,
3'-diaminobenzidine and counterstained with hematoxylin.
The sections were washed, dehydrated, and mounted as
routine.
Immunohistochemical scoring
For each stained section, the fraction of the immuno-
stained cells was recorded, and the staining intensity was
then initially categorized according to arbitrarily prede-
fined criteria into three ranks, including: 0, very weakly
or weakly positive; 1, moderately positive; and 2, strongly
positive. Five high power fields (×400) were randomly
selected in each section, and no fewer than 1,000 tumor
cells were observed. The percentage of positivity was cal-
culated. The percentage was scored from 0 to 4
according to the percentage of positive cells (0, 0-5%; 1,
6-25%; 2, 26-50%; 3, 51-75%; 4, 76-100%). Positive per-
centage score plus stain intensity score were the final
score of each section [14,15]. The examiners were
blinded to patients’ clinical and histological (HE staining)
profile. Two investigators evaluated the staining levels
independently, after which any discordant evaluations
were adjusted by connected microscopes and scored
jointly.
Single strand cDNA synthesis
Trizol (Invitrogen) was used to isolate total RNA from
cultured cells and tissue blocks following the manufac-
turer’s instruction. RNA integrity was confirmed spec-
trophotometrically and by electrophoresis on 1% agarose
gels [16]. For cDNA synthesis, 2 μg total RNA of a
sample were reverse-transcribed in a final reaction vol-
ume of 25 μL containing M-MLV (Promega), random
hexamers, dNTP, RNase inhibitor (TaKaRa). The reverse
transcription reaction was performed under the follow-
ing conditions: 70°C for 5 min followed cooling the tube
immediately on ice; then at 25°C for 10 min, 37°C for
1 h, and 85°C for 15 min.
Real-time PCR
CTTN and GAPDH (glyceraldehyde phosphate dehy-
drogenase) gene were amplified by RT-PCR (reverse
transcription-polymerase chain reaction) from one HCC
samples. The products of each gene were respectively
inserted into pMD18-T vector to build standard curves.
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spectrophotometrically. The primer set 5’-TGAGTGTG
TGTTCTTCCCCAAG-3’ (forward) and 5’-CACGTG
ACCTTCTGGAAAGACA-3’ (reverse) [6] was used for
CTTN. For standardization among the samples, GAPDH
was used as internal reference gene and the expression
of GAPDH in each sample was quantified by primer set
5’-AGAAGGCTGGGGCTCATTTG-3’ (forward) and 5’-
AGGGGCCATCCACAGTCTTC-3’ (reverse). 2 × SYBR
Premix Ex Taq (TaKaRa DRR041) was used and the re-
action was performed at least three times for each sam-
ple. For the signal detection, Eppendorf Mastercycler ep
realplex was programmed to an initial step of 10 s at
95°C and 40 thermal cycles of 5 s at 95°C, 25 s at 58°C,
and 15 s at 72°C. After PCR reaction, melting curve reac-
tion was performed. For analyzing the correlation between
CTTN mRNA expression level and HCC invasiveness,
the CTTN relative value to housekeeping gene GAPDH
was calculated. One hemangioma-neighboring liver tissue
sample became the 1× sample, and all the other quantities
were expressed as an n-fold difference relative to this
tissue.
Statistical methods
Data are expressed as means ± SE. The level of cortactin
mRNA in HCC cell lines and liver epithelial cell line
was compared using unpaired t-test. The correlations
between cortactin expression and clinicopathological
features were analyzed by Pearson χ2 test and unpaired
t-test. To compare the difference of CTTN mRNA
relative magnitude, the variance analysis and Kruskal-
Wallis rank sum test was used. Cancer-specific survival
time was calculated according to the Kaplan-Meier
method. The log-rank test was used to compare the
groups. P <0.05 was considered significant. All these
analyses were performed using SPSS 17.0.
Results
Invasiveness and motility
Compared with QSG-7701, a non-cancerous liver epi-
thelial cell line, the HCC cell lines HepG2, LM3, and
SK-Hep-1 had more invasiveness (P <0.01). But not all
HCC cell lines had significant invasiveness such as
MHCC97-L (P >0.05). (Figures 1 and 2) The metasta-
sis ability of HepG2, LM3, and SK-Hep-1 were alsoFigure 1 Decoration of puncture cells by five cell lines (100 ×magnifisignificantly superior to QSG-7701 (P <0.01, P <0.01,
P <0.05). MHCC97-L had poor metastasis ability (P >0.05)
(Figures 3 and 4).CTTN quantity method
The CTTN quantitative standard curve had finer linear
relation when copy number of standard products was
1.6 × 103-1.6 × 107, as well as GAPDH of 1.6 × 104-
1.6 × 107. R2 of both curves were >0.99. Single peak in
the melt curve identified specific PCR amplification.
CTTN specific peak localized at 88.0°C and GAPDH at
87.2°C. Preliminary test was performed to evaluate the
repeatability of CTTN quantity method before the final
detection. Five specimens of HCC were detected at 4
different days with three repetitions each run. Thresh-
old cycle values (Ct) were collected to statistics the
data. The outcome showed that the repeatability of
each specimen had no significant difference within run
and between days (data not shown).CTTN expression in HCC cell lines
The amplification products of each cell lines were
electrophoresed in 1.5% agarose gel to indicate correct
amplification (Figure 5). ALL HCC cell lines have dif-
ferent expression levels of CTTN mRNA. Compared
with QSG-7701, the CTTN mRNA of HepG2, LM3,
and MHCC97-L overexpressed to 4.86-517.75 times
(P <0.01). SK-Hep-1 had low expression of 0.63 times
(P <0.05) (Figure 6).Cortactin expression in HCC tissues
Among the 91 HCC tissues, cortacin positivity was ob-
served in most sections. Only two cases were completely
negative. Forty-three cases scored 0 to 3 and 48 cases
scored 4 to 6. In positive sections, cortactin immu-
noreactivity was detected on cytoplasm and showed dif-
fuse staining. On positive cells, the cell membrane also
showed positive staining with similar intensity of cyto-
plasm (Figure 7). Non-tumorous hepatocyte was almost
negative regardless of chronic hepatitis or cirrhosis.
However, bile duct epithelial cells and vascular endothe-
lial cells always stained strongly. This could ensure the
correct staining and the following scoring.cations).
* P>0.05, ** P<0.01
Figure 2 Counted number of puncture cells with five cell lines.
QSG-7701 was the control cell lines, *P >0.05, **P <0.01.
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No significant difference was detected in gender, age,
HBsAg, AFP, liver cirrhosis, tumor size, Edmondson
classification, number of tumor nodules, and liver cap-
sule integrity (P >0.05). On the contrary, statistical dif-
ference was detected in the cases with cancer embolus
in portal vein or distant neoplasm metastasis (P <0.001)
(Table 1).CTTN expression in HCC tissues
According to IHC analysis, we grouped the 91 HCC
cases by whether cancer embolus and metastasis could
be observed. Statistical results showed, although the
CTTN relative values of no cancer embolus and metas-
tasis group (N), cancer embolus or metastasis group
(Y), and control group (C) were tested normally dis-
tributed, the heterogeneity of variance existed between
groups (P <0.001). Kruskal-Wallis H test showed that the
relative magnitude was significantly different between
three groups. Paired comparison indicated the relative
magnitude of Y group was much higher than that of the
other two groups (P <0.001). There was no statistical sig-
nificance between the N and C groups (P >0.05) (Table 2,
Figure 8).Figure 3 Gap distance of scratch wound healing assay with five cell lSurvival analysis
The general median survival time of this group of 91
HCC patients was 37 ± 6.62 months. The authors carried
out survival analysis by the classification of Child-Pugh
grade. The result showed that grade A and B have a dif-
ferent median survival time of 43 ± 2.89 and 16 ± 5.28
months (P <0.001). In this group of data, only one pa-
tient was identified with grade C and survived 7 months
after the initial diagnosis and operation (Figure 9A).
According to BCLC stage system, three (3.3%) patients
were identified into group 0, 10 (11.0%) into group A, 22
(24.2%) into group B, 45 (49.5%) into group C, and 11
(12.1%) into group D. No patients died of HCC in group
0. The median survival times of groups A, B, C, and D
were 64, 44 ± 4.69, 25 ± 4.70, and 9 ± 2.75 months, re-
spectively. The significant deviation was found between
the four groups (P <0.001). The median survival time of
group 0 and the standard error of group A could not be
calculated for the censored data (Figure 9B).
Survival analysis was performed by two grouping
methods, including by according to the CTTN relative
magnitude and cortactin IHC score. For the convenience
of statistical analysis, the natural logarithm of relative
magnitude (RMLN) of each HCC specimen was calcu-
lated. The critical value was set at 2. The difference be-
tween these two groups was detected (P <0.001) with
median survival time of 52 ± 8.17 months (RMLN <2)
and 20 ± 4.24 months (RMLN >2) (Figure 10A). With
IHC score grouping, it had also shown difference be-
tween the 0–3 and 4–6 groups (P < 0.001). The median
survival time was 52 ± 8.62 months and 20 ± 4.95 months,
respectively (Figure 10B).
Discussion
Recent research has shown that several tumor markers
in serum are applied for the detection and forecasting
on HCCs. The recommended screening strategy for pa-
tients with cirrhosis includes the determination of serum
α-fetoprotein (AFP) levels to detect HCC at an earlier
stage. However, AFP is not satisfactory for the poor sen-
sitivity and specificity. In addition to AFP, Lens culinarisines (50× magnification).
 * P>0.05, ** P<0.05, *** P<0.01 
Figure 4 Diversify of scarification area with growth of five cell
lines. QSG-7701 was the control cell lines, *P >0.05, **P <0.05,
***P <0.01.
* P<0.01, ** P<0.05
Figure 6 CTTN relative expression with five cell lines
(logarithm). QSG-7701 was the control cell lines, *P <0.01, **P <0.05.
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thrombin (DCP), glypican-3 (GPC-3), osteopontin (OPN),
and several other biomarkers (such as squamous cell car-
cinoma antigen-immunoglobulin M complexes [SCCA-
IgM], alpha-1-fucosidase [AFU], chromogranin A [CgA],
human hepatocyte growth factor, insulin-like growth fac-
tor) have been proposed as markers for the detection of
HCC. Although these markers have their diagnostic and
prognosis roles, none of them is optimal [17]. When used
together, the DCP and AFP assays increase the sensitivity
of detecting HCC in >85% of patients. The specificity of
the DCP assay appears to be superior to that of AFP [18].
Recently, there has been attention given to DCP because of
its role in detecting HCC metastases and recurrence. The
serum DCP level correlates with the presence of vascular
invasion or intrahepatic metastases. Furthermore, DCP has
been reported to be an independent prognostic factor for
recurrence and survival after hepatic resection and other
treatment. High DCP levels reflect the biologic aggressive-
ness and progression of HCC [18].
In addition to serum markers, the tremendous ad-
vances in the research on HCC tissues have shown ex-
pression difference in several genes. The most relevant
result is the identification of an HCC-related index
consisting of 13 genes (TERT, IGF2, GJB2, TEF, TIAM1,
CXCL12, TOP2A, A2M, PLG, ARF, PDGFRA, MKI67,
and THBS1), which allowed the diagnosis of HCC with aFigure 5 Electrophoresis of CTTN and GAPDH amplified
products with five cell lines.high sensitivity and a specificity of 100%. Therefore, mo-
lecular analysis was shown to be a valuable tool for diag-
nosing HCC [16]. Another research has reported that 12
genes were expressed differently in initial HCC versus
dysplastic nodules: five were overexpressed (TERT,
glypican-3, gankyrin, survivin, TOP2A) and seven were
subexpressed (LYVE1, E-cadherin, IGFBP3, PDGFRA,
TGFA, cyclin D1, HGF) [19]. The same applies for bio-
markers such as VEGF, angiopoietin 2, or the proto-
oncogene c-Kit. They can refine prognostic prediction
within statistical modeling but cannot yet be incorpo-
rated into assessment of an individual patient [12].
Cortactin was originally identified as one of the major
substrates for the protein kinase Src [20]. Cortactin
gene, CTTN (formerly designated EMS1), was identified
to be amplified in several human cancers leading to
cortactin overexpression [21]. It localizes in the 11q13
that is frequently overexpressed in breast and head and
neck cancers and is tied to poor prognosis [22]. The
amplification of 11q13 includes several molecular
markers frequently associated with higher pathological
stage, lymph node and distant metastasis, and decreased
survival [23-25]. Due to the ubiquitous presence in cell
motility structures, such as lamellipodia and invadopodia
[21,26], cortactin generates a great deal of interest in the
role in tumor invasion. Cortactin contains a proline-rich
region with c-Src tyrosine phosphorylation sites and a
SH3 domain at the COOH terminus [27]. It also con-
tains an N-terminal acidic region that binds to the
Arp2/3 complex [28]. Phosphorylation binding sites and
SH3 domain are necessary for both activation and regu-
lation of Arp2/3-complex-mediated branched actin as-
sembly [29]. In addition to directly regulating actin
assembly, cortactin also activates the neural Wiskott-
Aldrich syndrome protein (N-WASP), one of the stron-
gest activators of the Arp2/3 complex [30,31]. By using
transwell migration [9], wound closure [32], and single
cell motility, it has been demonstrated that cortactin can
enhance cell motility. On the other hand, siRNA against
Figure 7 Cortactin expression in HCCs (400× magnification). (A) Bile duct epithelial cells (thin arrow) were strong positive, whereas HCC
tissue (thick arrow) was negative. (B) Vascular endothelial cells (arrowhead) were positive with HCC tissue of weak positive expression. (C) HCC
tissue showed strong positivity with diffuse staining of cytoplasm. (D) HCC tissue showed strong positive. Cancer cells were in a state of chaos
with severe morphosis. Cancer embolus (double tail arrow) in portal vein can be seen.
Zhao et al. World Journal of Surgical Oncology 2013, 11:74 Page 7 of 11
http://www.wjso.com/content/11/1/74cortactin inhibits cell motility [33,34]. Resent research
suggest that cortactin may regulate endocytosis of
integrins and growth factor receptors [35] or secretion
of proteases [36] and extracellular matrix (ECM).
These regulations have effects on cell motility, which
dependent cell context.
Evidence shows that invasion is the most important
factor which can raise recurrence rate of HCC [37]. Dif-
fusion within or outside liver though portal vein, which
originated from invasion of malignant cells, indicates
poor prognosis of HCC [38]. Current studies demon-
strate that overexpression of cortactin was closely associ-
ated with intrahepatic metastasis in human HCC and
was a sensitive marker for HCC with intrahepatic metas-
tasis [6]. But now it is lack of clinical research concern-
ing the relation between CTTN expression level and
HCC survival. Furthermore, to the best of our know-
ledge, no molecule markers can predict HCC prognosis
independently and precisely. For this reason, we applied
IHC and real-time PCR to detect cortactin expression in
both protein and mRNA level with the intention of de-
veloping an efficacious approach to predict prognosis of
HCC patients.
First, we compared five cell lines upon invasiveness
and motility. The results showed that the invasion ability
of three HCC cell lines were superior to the liver epithe-
lial cell line. The motility of LM3, HepG2, and SK-Hep
-1 were superior to QSG-7701, whereas MHCC97-L was
not higher than that of QSG-7701. Interestingly, com-
pared with liver epithelial cells, the CTTN expression of
HCC cells may be overexpression, such as LM3, HepG2,
and MHCC97-L, or low expression, such as SK-Hep-1.
These results indicate that although CTTN overexpressionTable 2 CTTN relative magnitude of the three groups
Group n x ± SE
Control 20 6.54 ± 0.96
No cancer embolus and metastasis 52 7.75 ± 0.70
Cancer embolus or metastasis 25 19.73 ± 2.02
Levene test of homogeneity of variance: F = 10.57, P <0.001; Kruskal-Wallis H test: Hmay signify the higher invasiveness and motility, low ex-
pression may not be the sign of lower invasiveness and
motility. The phenomenon was also observed in the exam-
ination of human tissue samples.
Subsequently, we detected cortactin IHC reactivity of
HCCs. As our data showed, cortactin immunohisto-
chemistry score was significantly associated with cancer
embolus in portal vein and distant neoplasm metastasis,
by both separately analysis and jointly analysis. This re-
sult is accordant with that of the other authors [6,38,39].
Apart from cancer embolus and distant metastasis, it is
worth noting that liver capsule integrity may be the la-
tent correlation factor to cortactin expression, though
the P values were 0.054. A recent report has shown that
extracapsular penetration is an important prognostic fac-
tor in human hepatocellular carcinoma [40]. In fact, if
hemorrhage occurs because of spontaneous rupture in
HCC or tumor cells break through pseudocapsule and
form satellite lesion, the capsule integrity would defin-
itely be destructed. The AJCC/UICC TNM stage system
emphasize the role of neoplasm invasion and metastasis.
We suppose that is the reason of correlativity between
TNM stage and cortactin immunohistochemical reac-
tion. Thus higher cortactin immunohistochemical score
may imply higher TNM stage of HCC, which is signifi-
cant to the clinical decision-making for the treatment to
HCC.
This series of data also showed that CTTN mRNA ex-
pression level of cancer embolus or metastasis group (Y)
was higher than no cancer embolus and metastasis
group (N) and control group (C). But we found no dif-
ference between the N and C groups. This finding may




= 31.13, P <0.001.
Figure 8 CTTN relative magnitudes of no cancer embolus and
metastasis group, cancer embolus or metastasis group, and
control group.
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tected results from HCC cell lines, CTTN expression in
MHCC97-L, a low invasiveness cell line, had the mildest
upregulation. SK-Hep-1 is a special cell line that cannot
form solid tumor. Its CTTN mRNA expression was not
upregulation. We supposed that it is because cortactin
have the role in regulation of the adhesion between cells.
It has been reported that the adhesion regulated by
cortactin may be relative to CD44, an important mol-
ecule to signal other cell surface receptors involved in
regulating cell motility and invasion [33]. Thus, low ex-
pression of cortactin cannot promote the efficient adhe-
sion which cannot lead HCC cells to format solid tumor,
just as the biological behavior that SK-Hep-1 has.
In clinical practice, accurately predicting prognosis as
far as possible is very important to the therapeutic
decision-making for HCC patients. To investigate the
prediction power by cortactin and CTTN, we bring into
cortactin immunohistochemical score and natural loga-
rithm of CTTN mRNA relative magnitude (RMLN). The
survival analysis showed that both methods could dis-
tinguish the variance between high and low cortactin
expression. Moreover, the median survival time was
similar to each other. This congruous result furtherFigure 9 Survival analyses by Child-Pugh grade and BCLC stage. (A) K
A, B, and C (P <0.001); (B) Kaplan-Meier curves of 91 HCC patients groupeddemonstrated the forecasting role of cortactin in both
mRNA and protein level.
To preclude the confounding factor that hepatic func-
tional reserve contributing to the survivals, we performed
a survival analysis stratified by Child-Pugh grade. The
results showed that in the stratum with Child-Pugh grade
A, the median survival time was 55 ± 7.38 months in the
patients whose cortactin IHC score was 0–3; but it was
only 30 ± 7.18 months in the patients whose cortactin IHC
score was 4–6. The difference between the two cortactin
expression levels was significant (P <0.01) (Figure 11A). In
stratum with Child-Pugh grade B, the median survival
time was 28 ± 3.54 months and 12 ± 3.74 months in levels
with cortactin scores of 0–3 and 4–6, respectively. How-
ever, the difference between these two cortactin expres-
sion levels was not significant (P = 0.071) (Figure 11B).
Hence the authors supposed that the decrease of hep-
atic functional reserve may reduce the survival time of
HCC patients with cirrhosis and it is a confounding fac-
tor when cortactin was applied to predict survival time
of patients.
Assessment of prognosis is a crucial step in manage-
ment of patients with HCC. The BCLC strategy has been
validated externally in prospective studies [41] and has
been endorsed by several scientific associations [12]. Here
the authors also analyzed the group of data which strati-
fied by BCLC stage system to understand the significance
of cortactin expression to the clinical stage. We simplified
the BCLC stage into two stages: 0-B and C-D. Survival
analysis stratified by simplified BCLC stage showed that in
the stratum with BCLC stage 0-B, the median survival
time was 63 ± 5.93 months in patients whose cortactin
IHC score was 0–3, which was much longer than those
whose IHC score was 4–6 (37 ± 12.73 months). The dif-
ference between the two IHC score levels was significant
(P = 0.015) (Figure 11C). In stratum with BCLC stage C-D,
the significant difference was not found between cortactin
IHC score level of 0–3 and 4–6 (P >0.05) (Figure 11D).
These results suggest that, cortactin examination can get
more accurate prediction in very early, early, andaplan-Meier curves of 91 HCC patients grouped by Child-Pugh grades
by BCLC stages 0, A, B, C, and D (P <0.001).
Figure 10 Survival analyses with two kinds of grouping method. (A) Kaplan-Meier curves of 77 HCC patients with CTTN RMLN grades of
<2 and >2 (P <0.001); (B) Kaplan-Meier curves of 91 HCC patients with cortactin IHC score ranks of 0–3 and 4–6 (P <0.001).
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and terminal HCC cases. The possible reason is that
BCLC stage C includes the cases that present vascular
invasion or extrahepatic spread. This criterion consequen-
tially weakens the power of cortactin forecasting role. Very
interestingly, this weakening also demonstrates on the
other hand that the high level of cortactin expression
in HCC identifies a high capability of invasion and
metastasis.
All the findings in our experiments support that
cortactin and CTTN expression levels are correlated
with the invasiveness and migration of HCC and give
the evidence that overexpression of cortactin and CTTN
mRNA contribute to HCC invasive and metastasis.
Cortactin examination has more predictive power in pa-
tients with Child-Pugh grade A and BCLC stage 0-B. In
addition to the satisfactorily predictive power to HCC
prognosis, we also develop a valuable method that canFigure 11 Survival analyses stratified by Child-Pugh grade and BCLC
A) with cortactin IHC score ranks of 0–3 and 4–6 (P <0.01); (B) Kaplan-Meie
score ranks of 0–3 and 4–6 (P = 0.071); (C) Kaplan-Meier curves of 35 HCC p
4–6 (P = 0.015); (D) Kaplan-Meier curves of 56 HCC patients (stratum BCLC Cprecisely detect CTTN mRNA level with the advantage
of sensitivity, specificity, and repeatability. This method
can be used for other quantitative studies about CTTN
expression. In conclusion, overexpression of cortactin is
closely associated with poor prognosis in human HCC.
Cortactin and CTTN should be used for differentiating
varieties of survival for patients with HCC.Conclusion
Overexpression of cortactin is associated with high inva-
siveness of hepatoma carcinoma cells, which closely in-
volved poor human HCCs prognosis that caused by
cancer embolus and metastasis. Cortactin examination
has more predictive power in patients with Child-Pugh
grade A and BCLC stage 0-B. As a sensitive biomarker,
cortactin should be used for differentiating varieties of
survival for patients after HCC resection.stage. (A) Kaplan-Meier curves of 68 HCC patients (stratum Child-Pugh
r curves of 22 HCC patients (stratum Child-Pugh B) with cortactin IHC
atients (stratum BCLC 0-B) with cortactin IHC score ranks of 0–3 and
-D) with cortactin IHC score ranks of 0–3 and 4–6 (P >0.05).
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